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In vitro anticancer activity 
of hydrogen sulfide and nitric 
oxide alongside nickel nanoparticle 
and novel mutations in their genes 
in CRC patients
Zjwan Housein1,2, Tayeb Sabir Kareem3 & Abbas Salihi1,4*
This study was carried out to assess the impact of nickel nanoparticles (NiNPs) as well as scorpion 
venom on colorectal cancer (CRC) cells in the presence and/or absence of 5-fluorouracil (5-FU), 
hydrogen sulfide  (H2S), and nitric oxide (NO) donors and to determine alterations in endothelial 
NO synthase (eNOS) and cystathionine γ-lyase (CSE) enzyme-producing genes in CRC patients. The 
 IC50 of both  H2S and NO donors, along with NiNPs, were determined. The CRC cells were treated for 
24hrs, and the cytotoxic activities were assessed using the MTT test. Moreover, the apoptosis was 
determined after 24hrs and 48hrs using TUNEL assay. Furthermore, the mutations in the eNOS gene 
(intron 4, -786T>C and 894 G>T) and CSE gene (1364GT) were determined using direct sequencing. 
The  IC50 values for sodium disulfide  (Na2S) and sodium nitroprusside (SNP) at 24hrs treatment 
were found to be 5 mM and  10−6 M, respectively, while the  IC50 value for 5-FU was reached after 
5-days of treatment in CRC cell line. Both black and yellow scorpion venoms showed no inhibition 
of cell proliferation after 24hrs treatment. Furthermore,  Na2S showed a significant decrease in cell 
proliferation and an increase in apoptosis. Moreover, a co-treatment of SNP and 5-FU resulted in 
inhibition of the cytotoxic effect of 5-FU, while a combination treatment of NiNPs with  Na2S, SNP, 
and 5-FU caused highly significant cytotoxicity. Direct sequencing reveals new mutations, mainly 
intronic variation in eNOS gene that has not previously been described in the database. These findings 
indicate that  H2S promotes the anticancer efficiency of 5-FU in the presence of NiNPs while NO has 
antiapoptotic activity in CRC cell lines.
In the world, colorectal cancer, generally known as colorectal adenocarcinoma, is the third foremost identified 
malignant tumour and the second most common cause of cancer death with variation within world  regions1,2. 
Contemporary, there is insufficient data available about the prevalence and deaths of CRC in the entire Kurd-
istan region of  Iraq3. The first report about CRC incidence in Kurdistan found an increase in annual incidence 
throughout 2007–20094. According to a study accomplished in the Kurdistan region of Iraq, CRC is the top 
four most common cancer type for both genders, and the mortality rate was 8.6% compared to the worldwide 
estimated mortality which is 9.2%1,5.
Hitherto, the stage of CRC is the most vital prognostic factor for surviving this disease and the treatment 
procedures for CRC are mainly surgical resection as long as cancer has not spread to distant organs followed 
by chemotherapy if  necessary6,7. Over the last three decades, 5-FU is used as a core chemotherapy drug to treat 
patients suffering from CRC 8. Other treatments like  radiotherapy9, ancillary anticancer medicines to prevent 
 relapse10, and combination  treatments11 are applied to treat patients in a more advanced stage of CRC. Neverthe-
less, all these therapy pathways have their drawbacks; therefore, innovative therapeutic approaches are requested 
 urgently12. Hence, investigators focused on natural resources such as scorpion venoms that contain a blend 
of toxins and catalytic enzymes which exhibit anticancer activities, and therefore, are considered a potential 
OPEN
1Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region 44002, 
Iraq. 2Department of Medical Laboratory Technology, Health Technical College, Erbil Polytechnic University, Erbil, 
Iraq. 3College of Medicine, Hawler Medical University, Erbil, Iraq. 4Department of Medical Analysis, Faculty of 
Science, Tishk International University, Erbil, Iraq. *email: abbas.salihi@su.edu.krd
2
Vol:.(1234567890)
Scientific Reports |         (2021) 11:2536  | https://doi.org/10.1038/s41598-021-82244-x
www.nature.com/scientificreports/
candidate for developing new drugs that could enhance the effectiveness of conventional therapy and enable 
reduction of high doses of chemotherapy drugs  intake13.
Recent researches are focused on tumour targeting through nanotechnology, which is a novel strategy and 
is a promising tool for the treatment of CRC 14. Nanoparticles are small in size and therefore transport easily 
through the cell and could remain inside the cancerous cell and destroy it with limited damage to the healthy 
cells and tissues. This target-specific character is an important factor for developing nanodrug for the treatment 
of colorectal cancer; however, there are limited studies available that evaluate the cytotoxicity of nickel nano-
particles (NiNPs) on CRC  cells15.
Hydrogen sulfide  (H2S) and Nitric oxide (NO) are gaseous molecules known as "gasotransmitters"16; they have 
various roles in normal human physiology and regulation of cancer-related events such as proliferation, angio-
genesis, cell apoptosis, and  metastasis17–19. Different enzymes endogenously catalyze each of these molecules in 
various cell  types20.  H2S is mainly raised from the amino acids L-cysteine by two separate enzymes cystathionine 
γ-lyase (CSE) and cystathionine β-synthase (CBS). At the same time, NO is enzymatically catalyzed by one of 
the four major isoforms of NO synthases, namely neuronal NOS, inducible NOS (iNOS), and endothelial NOS 
(eNOS) and lately mitochondrial NOS from the amino acid L-arginine and  oxygen21,22.  H2S and NO reveal the 
exceptional capability to diffuse free through the cell membranes, accordingly acting as regulatory signalling 
molecules and it turns out to have a paradoxical effect in the cells, being either promotive or suppressive reliant 
on cell types and the concentration and which pathway is consequently  activated21,23.
The findings in studies regarding the effect of NO and  H2S on CRC cell death and related angiogenesis are 
 ambiguous24,25. Hence, this study aims to find out the impact of venoms and nickel nanoparticles (NiNPs) on 
CRC cells treated with or without 5-FU,  H2S, and NO donors or a combination of these treatments. Further-
more, to evaluate the genotypic variations and polymorphisms in eNOS and CSE enzyme-producing genes in 
CRC patients.
Results
Anticancer activity of scorpion’s venom. The in vitro cytotoxic effect of crude black scorpion venom 
(Androctonus Crassicauda) and yellow scorpion venom (Hottentotta Saulcyi) was conducted in a dose-depend-
ent manner using CRC cell line (HT-29). The indirect measure of cell viability was determined using MTT assay. 
Both scorpion venoms showed no inhibition of cell proliferation after 24hrs treatment (Fig. 1).
Anticancer activity 5-FU,  Na2S, and SNP. The cytotoxic effect of 5-FU,  Na2S, and SNP was determined 
in a dose-dependent manner to obtain an appropriate concentration of these agents for 50% cell death using 
MTT assay. This dose concentration represents the  IC50 of that specific agent in the HT-29 CRC cell line after 
24hrs of exposure. The cell viability of each drug or agent and after treatment with the particular drug or agent 
or a combination of treatment were assessed. The  IC50 values for  Na2S and SNP at 24hrs treatment were found 
to be 5 mM and  10−6 M, respectively. Furthermore, we confirmed that the  IC50 value for 5-FU was 11.25 µM and 
reached after 5-days of treatment in the case of the HT-29 cell line.
Next, we investigated the cytotoxic effect of these agents and the drug individually or in combination treat-
ments on the HT-29 CRC cell line (Fig. 2). Our result presents the highly significant (P < 0.001) cytotoxic effect 
of 5-FU and a combination of 5-FU and  Na2S compared to the control cells. At the same time, treatment with 
5-FU and a combination of  Na2S and SNP shows significant (P < 0.05) more cell death compared to cells treated 
with individual  Na2S. Moreover, a co-treatment of  Na2S and 5-FU shows a highly significant (P < 0.001) cytotoxic 
effect compared to cells treated with only  Na2S.
A further data analysis showed that co-treatment of  Na2S and SNP causes highly significant (P < 0.001) cyto-
toxicity compared to cells treated with only 5-FU, whereas co-treatment of 5-FU and SNP decreases (P < 0.01) 
the cytotoxic effect compared to 5-FU, but the effect remains significant.
Figure 1.  Cytotoxic effect of crude scorpion venom on CRC cell line. The cell viability after treatment for 
24hrs on the HT-29 CRC cell line with Hottentotta Saulcyi scorpion venom (Black scorpion) and Androctonus 
Crassicauda scorpion venom (yellow scorpion), respectively.
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Our data also shows that co-treatment of  Na2S and SNP induces a highly significant (P < 0.001) cytotoxic 
effect compared to a co-treatment of 5-FU and  Na2S. While there is a decrease in cell cytotoxicity in co-treatment 
of 5-FU,  Na2S, and SNP (P < 0.05) compared to  Na2S and SNP treated group. Finally, CRC cells treated with a 
combination of 5-FU and  Na2S show a highly significant (P < 0.001) cytotoxic effect compared with the co-
treatment of 5-FU and SNP.
Anticancer activity NiNPs. We also investigated the cytotoxic effect of NiNPs on the HT-29 cell line using 
MTT assay for 24hrs (Fig. 3). Individual NiNP treatment has no cytotoxic activity in the HT-29 CRC cell line. 
In contrast, there is a highly significant increase (P < 0.001) in cytotoxicity in cells treated with a combination 
of  H2S, SNP, 5-FU, and NiNP compared to the control group. The further data analysis showed that there is a 
significant increase (P < 0.01, P < 0.05, and P < 0.05) in cytotoxicity of cells co-treated with  Na2S, SNP, 5-FU, and 
NiNP compared to co-treatments  Na2S, NiNP; SNP, NiNP, and SNP;  Na2S and NiNP, respectively.
Antiapoptotic activity 5-FU,  Na2S, and SNP. The DNA fragmentation results after 24 h incubation 
(Fig. 4) showed DNA fragmentation around 1–2%, in the control group, while the tunnel staining presented an 
increase of DNA fragmentation to 12% after treatment with  Na2S. Besides, tunnel staining exhibited an antia-
poptotic effect of CRC cells treated with SNP. Treating the cells with 5-FU causes total destroying of CRC cells 
after 24hrs, therefore only the debris of cells was visible in the slides. This result was almost the same for cells 
treated with both 5-FU and  Na2S. In the presence of SNP agent, the cytotoxic effect of 5-FU is inhibited, and 
more CRC cells survived. The effect of a triple combination of 5-FU,  Na2S, and SNP showed a distinctly decrease 
in cell survival, and more DNA fragmentation was visible.
We then investigated the DNA fragmentation after incubation of cells for 48hrs with  Na2S, a slightly increased 
DNA fragmentation was shown compared to 24hrs exposure (Fig. 5).
Figure 2.  Cytotoxic effect of NiNPs on CRC cell line. The cell viability after treatment with NiNP for 24hrs 
on the CRC cell line (HT-29). The *, †, Ω and ¥ indicates statistical significance difference from control, 
 Na2S+NiNP, SNP+NiNP, and  Na2S, SNP+NiNP, respectively.
Figure 3.  Cytotoxic effect of 5-FU,  Na2S and SNP and combination of these treatment on CRC cell line (HT-29) 
after 24hrs. The *, †, Ω, ¥, † and ¶ indicates statistical significance difference from control,  Na2S, SNP, 5-FU,  Na2S 
and SNP, and 5-FU and  Na2S, respectively.
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Genetic polymorphisms of eNOS and CBS. The result of gel electrophoresis in which the PCR product 
was separated in a 3% gel concentration, showed differences in the thickness of the amplicon. However, we were 
not able to distinguish between the heterozygous and homozygous variants. Therefore, we decided to genotype 
the three different single nucleotide polymorphisms in the eNOS gene and one in the CSE gene. Following DNA 
sequencing, we analyzed the mutations in eNOS and CSE gene using Mutation Surveyor (Table 1).
In total, we validated 19 mutations in the 27-bp repeat polymorphism in intron 4 (27 bp-VNTR) of the eNOS 
gene at a different position on chromosome 7. The most nucleotide substitution that occurred in the 27 bp-
VNTR was five times A→G. The variant mutation (c.582+317A>G) on chromosome position 7:150694330 has 
been previously described in external public databases such as dbSNP, gnomAD (Table 1). However, the A→G 
substitution in the mutation variants (c.582+360A>G, c.582+363C>A and c.582+362A>G) were not found in 
the external databases.
The T→G substitution (c.582+357T>G) on chromosome position 7:150694370 has occurred in two different 
CRC patients, and this mutation has been previously described; while, the T→G substitution with mutation vari-
ant (c.582+376T>G) that occurred on chromosome position 7:150694389, in which this mutation was not found 
previously in the databases mentioned above. However, the intronic nucleotide substitution A→C (582+355A>C) 
Figure 4.  HT-29 CRC cell death detection by TUNEL assay after 24hrs. Apoptotic cells presented 
their morphology by taking up fluorescent dye. (A) The nucleus of untreated cells stained with DAPI 
(100 × magnification). (B) Control. (C) Cells treated with  Na2S  (IC50: 5 mM). (D) Cells treated with SNP 
 (IC50: 10-6 M). E. Cells treated with 5-FU (11.25 µM after five days). (F) Cells treated with the combination 
of 5-FU and  Na2S. (G) Cells treated with the combination of 5-Fluorouracil and SNP. (H) Cells with the triple 
combination of 5-Fluorouracil,  Na2S, and SNP (images B-H at 1000 × magnification).
Figure 5.  HT-29 CRC cell death detection by TUNEL assay after 48hrs. Apoptotic cells presented their 
morphology by taking up a fluorescent dye. (A) control. (B) cells treated with  Na2S  (IC50: 5 mM). (C) Cells 
treated with SNP  (IC50.  10−6 M). (D) Cells treated with 5-FU (11.25 µM after five days). (E) Cells treated with the 
combination of 5-FU and  Na2S. (F) Cells treated with the combination of 5-FU and SNP.G. Cells with a triple 
combination of 5-FU,  Na2S, and SNP (images at 1000 × magnification).
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and G→A (c.582+356G>A) took place in the equal frequency of two, and G→C substitution (c.582+375G>C) 
turned out to occur only once in our patients that has not earlier been described in the databases.
Correspondingly, two deletions occurred in intron 4 including a single nucleotide deletion A (c.582+360delA) 
along with ten nucleotide deletions (c.582+374del TGC TGC GGGG). Furthermore, an heterozygous insertion 
of twenty-eight nucleotides occurred in intron 4 (c.582+381_c.582+382het_ins AGT CTA AAC CTA CTG CGG 
GGG TGA GGA) followed by a duplication of nucleotide A (c.582+620dupA). All these deletions and insertions 
found in intron 4, were not described previously in external databases. The G→A substitution that leads to 
homozygous mutation genotype were found in intron 4, and this mutation has been described in both dbSNP 
and gnomAD database.
Alongside the Intronic mutations in the eNOS locus, we studied mutations in a T to C single nucleotide poly-
morphism (SNP) in the promoter region (T-786C, rs2070744). We found six times the heterozygous nucleotide 
substitution C>T (c.-51-762C>T) and two homozygous mutations that have been previously described in a public 
database (Table 1). The difference between the homozygous and heterozygous substitution is demonstrated in 
Fig. 6a,b, respectively. Besides, we determined the genotype of G→T (Glu298ASP; rs1799983) polymorphisms 
in exon 7 of eNOS. Further analysis of our data revealed that a missense mutation occurred in 2 out of 5 patients 
in which guanine is replaced by thymine at exon 7 that leads to a different codon that changes the amino acid 
Glutamate into Aspartate at codon position 298. This mutation is known in the external database, and this mis-
sense mutation is shown in Fig. 6c
Last but not least, we identified a common single nucleotide polymorphism, namely c.1364G>T in exon 
12 of CSE, rs1021737 in CRC patients. The missense heterozygous SNPs (c.1208G>GT) on chromosome 
position1:70904800 causing a change in amino acid Ser to Ile at position codon position 1218 (Fig. 6d) and 
this mutation is earlier described in databases such as gnomAD, ClinVar, and dbSNP, while mutation variant 
(c.1218+247G>GA) that occurred on chromosome position 1:70905057 have not been found in database.
















7:150,694,330 A>AG AG Heterozygous c.582+317A>G N/A Intron variant gnomAD,dbSNP
7:150,694,368 A > AC AC Heterozygous c.582+355A > C N/A Intron variant Not found
7:150,694,369 G > GA GA Heterozygous c.582+356G > A N/A Intron variant Not found
7:150,694,370 T > TG TG Heterozygous c.582+357T>G N/A Intron variant dbSNP
7:150,694,373 Deletion A -A c.582+360delA N/A Intron variant Not found
7:150,694,373 A > AG AG Heterozygous c.582+360A > G N/A Intron variant Not found
7:150,694,376 C > AG AG Heterozygous c.582+363C > A+582+363C > G N/A Intron variant Not found




TGC TGC GGGG – –
c.582+365_
c.582+374
del TGC TGC GGGG 
N/A Intron variant Not found
7:150,694,375 A > AG AG Heterozygous c.582+362A > G N/A Intron variant Not found




AGT CTA AAC 
CTA CTG CGG 




AGT CTA AAC CTA CTG 
CGG GGG TGA GGA 
N/A Intron variant Not found
7:150,694,389 T > TG TG Heterozygous c.582+376T>G N/A Intron variant genomAD,dbSNP




AGT CTA AAC 
CTG CTG CGG 
GGG TGA GGA 
+ Heterozygous
c.582+381_c.582+
382het_ins AGTCT AAA 
CCT GCT GCG GGG GTG 
AGGA 




C > CT CT Heterozygous c.51-762C > T
c.51-762C > T




C > T TT Homozygous N/A dbSNP
eNOS
rs1799983 




1:70,905,057 G > GA GA Heterozygous c.1218+247G > A (Ser403Ile) Missense variant
Missense variant
Not found
1:70,904,800 G > GT GT Heterozygous c.1208G > T (Ser403Ile) dbSNP
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Discussion
Colorectal cancer remains one of the most common cancers in humans with high incidence and mortality across 
the world. The existing conventional chemotherapeutic agents exhibit shortcomings due to the lack of selective 
targeting of cancerous cells. For this reason, researchers are working towards target therapy for the development 
of the most effective treatment.
For decades, scorpion venom has been used in traditional treatments, and recently researchers exhibited the 
anticancer properties of scorpion  venom26. In this study, we examined the cytotoxic effect of the crude scorpion 
venoms, including Androctonus Crassicauda and Hottentotta Saulcyi on the CRC cell line (HT-29). The find-
ings of this study showed no inhibition of cell proliferation after 24hrs treatment with high concentrations of 
scorpion venoms. This result is in contrast to previous studies wherein they showed cytotoxicity and cell cycle 
arrest of scorpion venom (Androctonus bicolor) on breast and CRC cell  lines27. Moreover, Zargan et al. used 
Figure 6.  Graphical display of identified SNPs in eNOS and CSE gene (Sanger sequencing and analysis by 
mutation Surveyor software version 5.1. intronic mutation (VNTR4). Line 1 represents the forward reference 
trace Line 2 the patient DNA trace and line 3 the mutation trace and the arrow show the nucleotide substitution. 
(A) shows the heterozygous mutation -786T>C (c.-51-762C>T). (B) homozygous (T-786C) (c.-51-762C>T). 
(C) homozygous mutation in SNP G896T that leads to amino acid change (Glu298ASP) and (D) shows the 
mutation in SNP (364G-T) of the CSE gene that leads to amino acid change (Ser403Ile).
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Androctonus crassicauda scorpion, and their findings showed cytotoxicity and cell cycle arrest in the transformed 
breast cancer cell  line28.
Furthermore, a variety of anticancer effects such as inducing apoptosis, cell cycle arrest, along with inhibition 
of invasion, metastasis, and angiogenesis in cancer cells, which are all targets of hallmarks of cancer alters when 
a variety of cell lines are treated with different bioactive peptides of scorpion venoms as reviewed  recently29. 
The disability of both venom in this study to cause cytotoxicity could attribute to the venom preparation in 
this explicit investigational setup, where the venom is directly used after extraction from the scorpion without 
freeze-drying.
One of the main chemotherapeutic treatments for CRC includes 5-FU. The current result shows highly 
significant cytotoxicity of 5-FU on the HT-29 cell line. This is consonance with the recently published work by 
Attoub e al. wherein they demonstrate a reduction of different human CRC cells after treatment with 5-FU30. 
Nonetheless, the clinical application of 5-FU often causes chemoresistance. Therefore it is necessary to pursuit 
combination therapy to minimize the side effects that occur in  patients31. The precise role of gasotransmitters 
 H2S and NO in cancer remains debatable and demands further attention. Several studies have ascertained that 
NO and  H2S have a dichotomous role in cancer, either promoting growth and proliferation. In contrast, others 
suggest antitumor effects such as inhibition of cell proliferation and suppression of DNA synthesis of the cancer 
cells as remarked by Kashefi in a recent  review32. Given the positive role of these two gasotransmitters in the 
inhibition of cancer cell proliferation, in the present study, we have investigated the effect of NO and  H2S donors 
individually or in combination with 5-FU on the HT-29 cell line for 24hrs.
Our data illustrates that  Na2S significantly increases the cytotoxicity of HT-29 cells after combination with 
5-FU compared to untreated cells. The findings in this study are in a similar vein with Oláh et al.24, who claim 
that using an increased level of  H2S above the optimum concentration suppresses CRC cell proliferation. How-
ever, this result is not in line with Szabo et al.33, who depict that  H2S stimulates tumour progression in the CRC 
cell line. In the same way as  H2S, we examined the cytotoxic effect of NO donor SNP on the CRC cell line. The 
result shows no cytotoxicity of SNP on HT-29 cells compared to untreated cells while eradicates the cytotoxic 
effect of 5-FU. The latter findings might indicate that SNP acts as an antiapoptotic agent and probably interact 
with 5-FU and abolish the cytotoxic effect of 5-FU, which makes HT-29 cells resistant to 5-FU. According to 
a recent review, NO acts according to the bell-shape model in a concentration-dependent manner similar to 
 H2S24. The interaction between  H2S and NO that leads to the production of  H2Sn has recently been studied and 
has shown that it could affect several physiological events such as activation of a particular tumour suppressor 
 gene34. Therefore, it is important to study the effects of  H2Sn in CRC cell lines and find the mechanism of action 
in future studies. Furthermore, the findings of a study that used a hybrid molecule containing nitric oxide and 
 H2S combined with aspirin (NOSH-aspirin) which has anti-tumour properties demonstrated a synergistic effect 
with 5-FU treatment in xenograft model of colon  cancer35.
To study the apoptosis induction from a different endpoint, we measured DNA fragmentation using the 
TUNEL assay. The results demonstrated a ten-fold increase in DNA fragmentation in HT-29 cells treated with 
 Na2S compared to the untreated cells, while 100% of the cells were killed using 5-FU or co-treatment with 
 Na2S and 5-FU. Our finding is in agreement with recently published in vivo work, wherein they demonstrate a 
significant increase in TUNEL positive cells after inhibition of  CBS36. Earlier published work has shown CBS to 
be overexpressed and promote cell proliferation and stimulate angiogenesis in CRC  patients33. These findings 
might propose the fact that these agents are acting as proapoptotic agents and could be a suitable candidate for 
future target therapy against CRC. In the meantime, treating HT-29 cells with SNP for 24hrs and 48hrs did not 
demonstrate any DNA breakage, while a co-treatment with 5-FU and SNP more cells survived. The latter finding 
is in line with our anticancer activity result wherein no effect of SNP was determined, and SNP neglected the 
cytotoxic effect of 5-FU. Besides, a triple combination treatment of 5-FU, SNP, and  Na2S showed an increase in 
DNA fragmentation and a decrease in cell survival. Perhaps,  H2S could be considered as a potent anticancer agent.
Nanoparticles have gained immense attention in the field of cancer therapy due to their small size and 
highly reactive and specific feature, and due to its target-specific character, it enables a personalized treatment 
as described in two separate  reviews37,38. Having discussed the positive role of NO and  H2S in colon cancer, we 
aimed to observe the anticancer activity of NiNP on HT-29 cells by measuring the cytotoxicity of the particles 
and in combination with 5-FU and the donors of these two gasotransmitters. Our result showed that there is 
no significant difference in cell survival after exposure of CRC cells to NiNP for 24hrs, while co-treatment of 
NiNP with 5-FU,  Na2S, and SNP shows a significant increase in cytotoxicity. Of note, SNP does not inhibit 5-FU 
cytotoxicity. These findings are inconsistent with a recently published work where they demonstrate reduced cell 
viability and apoptosis induction after treatment with high concentration (600 µg/ml) Nickel oxide (NiO) NPs 
in CRC cell lines including HT-2915. Several studies are indicating that nanoparticles are used for enhancement 
of the efficiency of 5-FU, however, to our knowledge there are no NiNPs used in combination with neither 5-FU 
nor the agents  H2S and NO and no data is available about the synergistic effect of  NiNP39.
The recognition of targetable mutations determines current developments toward individualized treatment. 
One of the new treatments for metastatic CRC (mCRC) patients is the Cetuximab which is a monoclonal anti-
body that acts explicitly on the epidermal growth factor receptor (EGFR). This treatment is applied to mCRC 
patients without a mutation in the RAS gene. The reason for this is that CRC patients with mutations in this 
particular gene will fail to respond to this target-direct  therapy40. Hence, a prescreen for the mutation before 
target therapy is mandatory.
In the current study, stage III and IV patients were screened for variants and polymorphisms in eNOS and CSE 
genes using a direct sequencing method. In this paper, the CSE gene will be reported as CTH according to the 
SNP database in NCBI. The eNOS gene has around168 polymorphism. We only analyzed three polymorphisms 
in eNOS genes and one polymorphism in the CTH gene that has been broadly studied in the literature. The 
genetic features of CRC patients are summarized in Table 1. The most prominent finding in our genotypic study 
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is that two patients have 10 and 12 mutations in intron 4 (including single substitution, followed by duplication, 
large insertions as well as deletion). The current findings demonstrate the majority of heterozygous substitutions 
are A>G followed by CG and TG. However, this is not in line with the records found in the COSMIC database 
where more than 50% of the substitutions are G>A followed by G>T and T>A in the adenocarcinoma sample 
tissue of the colon cancer patients. Moreover, it is worth noting that our result showed the least mutations rate 
occurrence in 894G>T variant of eNOS and CTH gen.
To the best of our knowledge, the majority of detected mutations that occurred in selected CRC patients are 
not seen in the public database yet (Table 1). This might indicate that novel mutations in eNOS and CTH are 
validated on a specific location on a chromosome, that not previously have been described.
The findings regarding the involvement of eNOS polymorphism in cancer are controversial, likely due to con-
sidered factors such as analyzed sample size, cancer type, and the ethnic-dependent  variation41. A meta-analysis 
study reported a significant association of eNOS intron 4, and -786T>C polymorphism in overall cancer and 894 
G>T polymorphisms with the risk of breast  cancer42. While another conducted meta-analysis study reported 
a conflicting result wherein they did not found a significant association of SNP 894 G>T with overall cancer 
 susceptibility43. Moreover, Ulivi and his colleagues claim to have identified a specific haplotype in eNOS poly-
morphism (+ 894GG and VNTR4) that are significantly associated with the overall survival of mCRC patients. 
Therefore, the researchers consider using this identified eNOS variant to predict the efficiency of bevacizumab-
based chemotherapy in mCRC  patients44, and a Chinese study confirmed a significant association between 
the intron 4 variant and increased cancer risk in Taiwanese individuals under the age of 60  years45. One of the 
limitations of this study is the restricted number of analyzed samples and SNPs used in this study that limits the 
evaluation of the results.
Conclusions
These findings reveal that  H2S could be used for enhancement of the anticancer efficiency of 5-FU in the presence 
of NiNPs in the CRC cell line, while NO could be considered as an antiapoptotic agent that enables HT 29 cells 
resistant to 5-FU treatment. Moreover, changing the experimental setup in future research by administrating 
loaded NPs or venom or a combination with  H2S in liposomes might deliver the agents more efficiently to the 
CRC cells leading to a better strategy of cancer treatment. Further investigation on the molecular level is essential 
to understand the mechanism by which the mutations in eNOS and CSE enzyme-producing genes perhaps could 
modify the role of  H2S and NO in CRC patients.
Materials and methods
Cell culture. The human colorectal adenocarcinoma (HT-29 cells, IBRC C10097) were purchased from the 
National Cell Bank in the Iranian Biological Resource Center. These cells were grown as a monolayer in a 25 
 cm2 culture flask with Dulbecco’s Modified Eagle Medium (DMEM high glucose, EuroClone cat: ECM0728L) 
containing L-glutamine. The culture media were supplemented with an antibiotic solution containing 1% (100×) 
Penicillin/Streptomycin (Capricorn Scientific Cat: PS-B) and 10% heat-inactivated FBS (Capricorn Scientific 
Cat: FBS-GI-12B) as the provision of nutrients. The cells were maintained at 37  Co in a 5%  CO2 humidified incu-
bator (RS Biotech Galaxy Model R +, USA). The growth medium was changed every three days, and the viabil-
ity of cells was assessed by direct observation of cells using an inverted phase-contrast microscope (Labomed, 
USA). The HT-29 cells were sub-cultured using 0.05% trypsin/EDTA (Capricorn Scientific cat: TRY-1B). Cell 
viability was assessed by staining 100 µl of cell suspension with trypan blue (0.2%), and cells were counted using 
a hematocytometer. All the experiments were performed using cells from passage 20 or less.
Cell morphology analysis. To find out the  IC50, the cells were treated with various concentrations 
of  Na2S, an exogenous  H2S donor, ranging from (1-6 mM), SNP a NO donor, with following concentrations 
(3 × 10–5–3 × 10−8  M) for 24hrs and 5-FU (11.25  µM) for 24, 48, 72hrs and 96hrs which expect to reach the 
 IC50 after five  days46. The morphological changes were examined using an inverted phase-contrast microscope 
(Labomed, USA) followed by MTT assay.
In vitro cell proliferation assay. The reduction of (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-2H-tetra-
zolium bromide) is a method to measure and monitor cell proliferation. MTT assays were performed using the 
Cytoselect MTT Cell Proliferation Assay (Cell Biolabs, Inc., Cat: CBA-252, San Diego, CA, USA). After reach-
ing 85% confluence, the HT-29 cells were trypsinized, and the cells were suspended in the growth medium, 
2 × 105 cells/well were seeded in a 96-well culture plate and incubated at 37 C° in a humidified 5%  CO2 allowed 
to attach for 48hrs. The cytotoxicity of the compounds was determined in a dose-dependent manner to obtain 
the proper concentrations of the compound for 50% inhibition of cell growth  (IC50). The growth medium was 
then changed with the new medium and exposed with  IC50 concentration of the compounds and exposed for 
24hrs at the following  IC50 concentrations:  Na2S (5 mM), SNP (1.10–6 M), 5-FU (11.25 µM, after five days), and 
the combination of these compounds and each condition is tested in 6 replications. After the incubation periods, 
10 µl of Cytoselect MTT cell proliferation assay reagent was added to each culture well, and the 96-well plates 
were incubated at 37  Co for 4hrs until a purple precipitate is visible. 100 µl of a detergent solution containing 
dimethylsulfoxide (DMSO) was added to each well to dissolve the purple formazan product. Following 2hrs of 
incubation at room temperature in the dark, the absorbance was determined at a wavelength of 630 nm by an 
Elisa reader (BioTek Instruments, Inc., USA).
Preparation of Nickel nanoparticle suspension. Nickel nanoparticle with 40 nm in diameter size from 
(Sigma-Aldrich Co, St Louis, USA) was tested in this study. The method described by Abdulqader and  Aziz39 
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was used to prepare NiNPs with some modification. Hence, a 1 mg/ml stock solution in the growth medium 
was prepared, and subsequently, the suspension was vortexed and then sonicated for 30 s with an ultrasonic 
homogenizer (150 VT model, constructed by Biologica, Inc., Manassas, VA, USA). Next, the suspension with 
nickel particles was placed on ice for 15 s, and, sonicated again for 3 min on ice. The NiNPs were vibrated for 
2 min, immediately before the actual incubation to avoid agglomeration. The HT-29 cells were incubated with 
NiNP suspension with the following concentrations (0.1–30 µg/ml) for 24hrs, and the  IC50 of (10 µg/ml) was 
determined. The  IC50 of NiNP was subsequently used for treating the cells with NiNP alone or co-treatment with 
 IC50 concentration of the following agents, including, 5-FU,  Na2S, and SNP.
Cell apoptosis assay. The terminal deoxynucleotidyl transferase (dUTP)-nick end labelling (TUNEL) 
method that determines DNA-strand breaks throughout the apoptosis process was used to confirm HT-29 cells 
undergoing apoptosis after treatment with different compounds for different time of period. Cell Meter TUNEL 
(Red fluorescence) Apoptosis Assay Kit (AAT Bioquest Inc., USA, Cat: 22,844) was used according to the manu-
facturer’s suggestion procedure with some modifications. In short, 6 × 104 of HT-29 cells were grown for 72hrs 
on coverslips then treated with or without  IC50 of the following compounds;  Na2S (5 mM), SNP  (10–6 M), 5-FU 
(11.25 µM, after five days), and the combination of these compounds for 24 h, 48 h, and 72 h, 96 h, and 105 h at 
37 °C with 5%  CO2. After incubation coverslips were rinsed twice with ice-cold PBS (pH 7.4) followed by incu-
bation with TUNEL kit reaction solution (consisting of 100× Tunnelyte Red 0.5 µl+ reaction buffer 50 µl) for 
45 min at 37  Co in a dark chamber and additional 4′,6-diamidino-2-phenylindole (DAPI) stain was conducted 
to identify the cell nuclei. Cells with red nuclei are TUNEL-positive indicating apoptosis and apoptotic cells were 
visually observed using a fluorescence microscope (Euromex, Holland) equipped with sCMEX-20 Microscope 
Camera (Euromex, Holland). The images of total cell nuclei stained with DAPI and CRC cells stained with 
TUNNEL fluorescent dye were captured at 100 × and 1000 × magnification, respectively. The quantity of TUNEL 
positive cells was given as a percentage of total cells counted in a minimum of six random microscopic fields.
Collection of scorpions and their venom. The scorpion species (Androctonus Crassicauda and Hotten-
totta Saulcyi) were collected from different regions of northern Iraq by a professional researcher. The scorpion 
collection and venom isolation were carried out in accordance with the Guide for the Care and Use of Labora-
tory Animals and approved by the Animal Research Committee of Salahaddin University-Erbil. These arachnids 
were kept individually within the desirable condition and sustained with mealworms and water ad libitum. The 
scorpion venoms were ejected by electrical stimulation and directly used to expose the HT-29 cells with venom 
concentrations ranged from (0.1–1.0 mg/ml) for a period of 24hrs.
Human CRC specimens. CRC specimens were collected from 35 patients at different hospitals in Erbil, 
Iraq (PAR, CMC, Rezgary, Zheen international hospitals). This study was approved by the Human Ethics Com-
mittee of the College of Science, Salahaddin University-Erbil. The study was conducted according to the criteria 
set by the declaration of Helsinki, and the signed informed consent forms were obtained from the participants 
approving to investigate the tissue material. All CRC were histologically confirmed, and the tissue specimens 
were snap-frozen in liquid nitrogen and stored at -80  Co until DNA extraction.
DNA extraction and quantification of DNA concentration. Genomic DNA was purified from CRC 
tissues following the manufacturer’s protocols using the Genomic DNA Mini Kit for Tissue (Geneaid Biotech 
Ltd, Korea). The eluted DNA was assessed for concentration (A260) and purity (by the measure of the A260/
A280 ratio) on Nanodrop (Thermo Fisher Scientific, UK). The Nanodrop instrument was blanked against the 
elution buffer, and the interpretation of DNA purity was based on an optimal A260/A280 ratio of 1.8.
Genotype determination. In this study, we selected three commonly studied variations in the eNOS gene 
and one CSE variant, also known as CTH, located on chromosome 7 (7q36.1) and chromosome 1 (1p31.1), 
respectively. We genotyped 25% of the collected sample tissues for eNOS genetic polymorphisms rs2070744 
(−786T>C) at the promoter region and 14% of the patient tissues for rs1799983 (894G>T), and 11% of the 
patient tissues for intron 4 27-base repeat variant (VNTR4). Furthermore, 14% of the genetic polymorphism 
rs1021737 of the CSE gene (1364GT) variant at exon 12 is genotyped.
First, the purified DNA was separately amplified for each genetic polymorphism by polymerase chain reaction 
(Techne TC-512, UK) using the following primers: eNOS (−786T>C) forward, 5′AAGGC AGG AGA CAG TGG 
ATGGA-3′ and reverse, 5′-CCC AGT CAA TCC CTT TGG TGC TCA-3′. eNOS (894G>T) forward, 5′-TGG AGA 
GTG CTG GTG TAC CCCA-3′ and reverse, 5′-GCC TCC ACC CCC ACC CTG TC-3′. eNOS (VNTR4) forward, 
5′-AGG CCC TAT GGT AG TG CCTTT-3′ and reverse 5′-TCT CTT AGT GCT GTG GTC AC-3′ and CSE (1364 G>T) 
forward, 5′-GGAC TTC TTG AGG AGT TGA AGC -3′ and reverse, 5′-ATT CTC ACC TCC TTC AGA GGC-3′. The 
PCR thermocycling conditions included an initial denaturation step at 95 °C for 5 min, followed by 35 cycles of 
95 °C for 30 s; different annealing temperatures were used for each polymorphism (-786T>C at 56 °C, 894G>T 
at 55 °C, VNTR4 at 55 °C and CSE 1364 G>T at 50 °C) for the 30 s; elongation at 72 °C for 1 min, and a final 
extension step at 72 °C for 5 min. All the PCR products were separated on 3% agarose gel electrophoresis and 
compared with the 50 bp DNA marker (Mini Sizer, Norgen Biotek Corp. Canada., cat:11200) and stained with 
safe dye (Safe gel stain Dye, Add Bio) before casting into the tray and visualized using a gel documentation system 
(UV transilluminator UST-20M-8K, Biostep GmbH, Germany).
Following the PCR procedure product was sent for sequencing using the same forward primers for each par-
ticular polymorphism by using automatic ABI PRISM 3130 DNA sequencer (Applied Biosystems, USA). Analysis 
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of Sanger sequencing data was achieved using the Mutation Surveyor software package 5.1 (Soft Genetics), and 
the mutation result was compared with public databases, including gnomAD, dbSNP, ClinVar, and COSMIC).
Statistical analysis. The results were analyzed using GraphPad Prism 6. One-way ANOVA with Tukey’s 
multiple comparisons test was conducted to evaluate the statistically significant differences between the antican-
cer activity of different agents and untreated cells. All the experiments were carried out 3 to 6 times and the data 
were stated as mean ± SE difference.
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